QUASR Diagnostics Marks Major Achievement with Technology Readiness Award

In a remarkable achievement, QUASR Diagnostics, which developed a platform to commercialize the next generation of rapid molecular diagnostic tests, has reached a pivotal milestone by successfully concluding its Technology Readiness Award. This accomplishment marks a significant stride towards bringing their technology to the forefront of healthcare, with a particular focus on addressing pressing issues in the realm of respiratory diseases.

QUASR Diagnostics is a leading player in the field of clinical diagnostics, specializing in QUASR assays — an innovative point-of-care molecular diagnostic platform. These assays offer rapid results, often within 20-30 minutes, while maintaining the sensitivity of traditional PCR tests. The company’s mission is clear: to provide accessible, timely, and accurate diagnostic solutions that empower individuals and healthcare professionals to make informed decisions about their health.

Completing the Technology Readiness Gross Receipts (TRGR) award is a significant achievement for QUASR Diagnostics. This award is part of a partnership with Sandia National Laboratories, where QUASR Diagnostics licensed the technology. The TRGR is designed to expedite the development of technologies deemed ripe for commercialization and is funded by the government as part of the Technology Readiness Initiative.

Attaining the TRGR is not a simple feat. Companies like QUASR Diagnostics apply for this grant with a clear focus on advancing their technology. In QUASR’s case, the award was granted after nearly a year to facilitate the development of assays for respiratory diseases. 

Winning the TRGR award serves as a powerful testament to QUASR’s technology, affirming that it is not merely an innovative concept but a solution ready for commercialization. This recognition goes a long way in establishing QUASR Diagnostics as a credible player in the field, instilling confidence that its technology is poised to deliver on its promises.

Moreover, the TRGR award has been instrumental in expediting QUASR Diagnostics’ research and development (R&D) journey. Developing diagnostic tests is a complex process involving meticulous assay design, validation, and the critical evaluation of sensitivity and specificity. With the support of the TRGR grant, the company gained access to invaluable technical assistance. This not only eased the financial burden but also significantly reduced the time required to bring their assays to the market, aligning perfectly with the urgency of healthcare needs.

The focus of the TRGR grant on respiratory diseases, including the pivotal COVID-19, influenza A, and influenza B, has been particularly timely and relevant. Amid the evolving healthcare landscape characterized by respiratory disease outbreaks, this specialized focus has allowed QUASR Diagnostics to channel its efforts where they matter most. It positions them as key contributors to addressing these pressing healthcare challenges.

Perhaps one of the most transformative aspects of the grant is the opportunity to collaborate with scientists from Sandia National Laboratories. This partnership has proven instrumental in advancing QUASR Diagnostics’ technology to the next level. The expertise and insights brought by these scientists have been invaluable, propelling the company closer to its goal of providing accessible, accurate, and rapid diagnostic solutions.

QUASR Diagnostics’ completion of the Technology Readiness Award is not just a milestone; it’s a testament to the company’s dedication and expertise in the field of diagnostic testing. It represents the culmination of rigorous research and development efforts, positioning their technology for commercialization. By winning this award, QUASR Diagnostics has not only enhanced its credibility but has also taken a giant leap toward delivering accessible, accurate, and rapid diagnostic solutions for the benefit of individuals and healthcare providers alike. To learn more about QUASR, visit their website.